A new European network for influenza vaccine effectiveness studies
Vaccines are the cornerstone of preventing influenza but their effectiveness varies.

Annual *vaccine effectiveness studies* are needed.
Multiple types of influenza vaccines on the market (and more on the way)

(trivalent, quadrivalent, live attenuated, high-dose, adjuvanted, cell-based ...)

---

IMI
Since 2017, the European Medicines Agency requires **brand-specific** influenza vaccine effectiveness results from manufacturers.

**EMA encourages industry to**

*liaise with public health authorities who have experience in influenza effectiveness studies and who have implemented a functioning infrastructure to conduct multicentre studies*
A sustainable study network for brand-specific influenza vaccine effectiveness studies in the EU

A governance model for transparent, scientifically robust public-private partnerships